natgillin/translations-raw huggingface dataset:
absolute neutrophil count ≥ 1.5 x 109/l; thrombocyte count ≥ 100 x 109/l; CTC non-haematological toxicity ≤ Grade 1 (except for alopecia, nausea, vomiting).
a: Istodobno liječenje temozolomidom može se nastaviti kada su zadovoljeni svi sljedeći uvjeti: apsolutni broj neutrofila ≥ 1,5 x 109/l; broj trombocita ≥ 100 x 109/l; nehematološka toksičnost prema CTC ≤ stupnju 1 (osim alopecije, mučnine i povraćanja).
Grade 3 or 4 thrombocytopenia and neutropenia occurred in 19% and 17% respectively, of patients treated for malignant glioma.
Laboratorijski nalazi Trombocitopenija stupnja 3 ili 4 razvila se u 19%, a neutropenija stupnja 3 ili 4 u 17% bolesnika liječenih zbog malignog glioma, što je dovelo do hospitalizacije i/ili obustave liječenja TMZ-om u 8% odnosno 4% bolesnika.
In patients previously untreated with chemotherapy, TMZ is administered orally at a dose of 200 mg/m² once daily for the first 5 days followed by a 23 day treatment interruption (total of 28 days).
U bolesnika koji prethodno nisu liječeni kemoterapijom, TMZ se primjenjuje peroralno u dozi od 200 mg/m2 jedanput na dan tijekom prvih 5 dana, nakon čega slijede
Temozolomide Teva 5 mg two stripes in green ink on the cap and “T 5 mg” in green ink on the body
Temozolomid Teva 5 mg dvije zelene linije na kapici i zelena oznaka “T 5 mg” na tijelu kapsule
Temozolomide Teva 20 mg two stripes in orange ink on the cap and “T 20 mg” in orange ink on the body
Temozolomid Teva 20 mg dvije narančaste linije na kapici i narančasta oznaka “T 20 mg” na tijelu kapsule
Uncommon (may affect up to 1 in 100 people): flu-like symptoms, red spots under the skin, low potassium level in the blood, weight gain, mood swings, hallucination and memory impairment, partial paralysis, impaired coordination, impaired sensations, partial loss of vision, dry or painful eyes, deafness, infection of the middle ear, ringing in the ears, earache, palpitations (when you can feel your heart beat), blood clot in the lung, high blood pressure, pneumonia, inflammation of your sinuses, bronchitis, a cold or the flu, swollen stomach, difficulty controlling your bowel movements, haemorrhoids, peeling skin, increased skin sensitivity to sunlight, change in skin colour, increased sweating, muscle damage, back pain, difficulty in urinating, vaginal bleeding, sexual impotence,
suhe ili bolne oči, gluhoća, infekcija srednjeg uha, zvonjava u ušima, bol u uhu, palpitacije (lupanje srca), krvni ugrušak u plućima, visok krvni tlak, upala pluća, upala sinusa, bronhitis, prehlada ili gripa, oticanje trbuha, poteškoće s kontroliranjem stolice, hemoroidi, ljuštenje kože, povećana osjetljivost kože na sunčevu svjetlost, promjena boje kože, pojačano znojenje, oštećenje mišića, bol u leđima, poteškoće s mokrenjem, vaginalno krvarenje, impotencija, izostanak ili obilne menstruacije,
Common (may affect up to 1 in 10 people): loss of weight, tiredness, dizziness, tingling sensation, shortness of breath, diarrhoea, abdominal pain, upset stomach, rash, itching, hair loss, fever, weakness, shivering, feeling unwell, pain, change in taste.
Česte (mogu se javiti u do 1 na 10 osoba): gubitak tjelesne težine, umor, omaglica, trnci, nedostatak zraka, proljev, bol u trbuhu, želučane tegobe, osip, svrbež, gubitak kose, vrućica, slabost, drhtavica,
CTC Grade 4b a:
CTC stupanj 4b a: doze TMZ-a navedene su u Tablici 2. b: TMZ se mora prekinuti:
Marketing Authorization Holder
NOSITELJ ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET
Each capsule is approximately 19.5 mm in length.
Svaka je kapsula duljine od oko 19,5 mm.
Each capsule is approximately 22 mm in length.
Svaka je kapsula duljine od oko 22 mm.
Excipient with known effect Each hard capsule contains 117 mg of lactose.
Jedna tvrda kapsula sadrži 117 mg laktoze.
Each capsule is approximately 16 mm in length.
Svaka je kapsula duljine od oko 16 mm.
Excipient with known effect Each hard capsule contains 209 mg of lactose.
Jedna tvrda kapsula sadrži 209 mg laktoze.
Red iron oxide (E172)
šelak propilenglikol željezov oksid, crveni (E172)
Once escalated, the dose remains at 200 mg/m² per day for the first 5 days of each subsequent cycle except if toxicity occurs.
Kad se jednom poveća, doza ostaje na razini od 200 mg/m2 na dan tijekom prvih 5
Asthenia, face oedema, pain, condition aggravated, rigors, tooth disorder,
Astenija, edem lica, bol, pogoršanje stanja, tresavica, promjene na zubima
Temozolomide Teva 5 mg hard capsules
Temozolomid Teva 5 mg tvrde kapsule
Abdominal distension, fecal incontinence, gastrointestinal disorder (NOS), gastroenteritis, haemorrhoids
Abdominalna distenzija, inkontinencija stolice, nespecificirani gastrointestinalni poremećaj,
Visual acuity reduced, eye pain, eyes dry
Smanjena oštrina vida, bol u oku,
Temozolomide Teva 250 mg hard capsules
Temozolomid Teva 250 mg tvrde kapsule
Each capsule is approximately 18 mm in length.
Svaka je kapsula duljine od oko 18 mm.
Temozolomide Teva 250 mg hard capsules Each hard capsule contains 250 mg temozolomide.
Temozolomid Teva 250 mg tvrde kapsule Jedna tvrda kapsula sadrži 250 mg temozolomida.
Hearing impairment
oštećenje sluha
Temozolomide Teva 20 mg hard capsules
Temozolomid Teva 20 mg tvrde kapsule
Temozolomide Teva 140 mg hard capsules
Temozolomid Teva 140 mg tvrde kapsule
CTC Non-haematological Toxicity (except for alopecia, nausea, vomiting)
CTC stupanj nehematološke toksičnosti (osim alopecije, mučnine i povraćanja) CTC stupnja 2
Temozolomide Teva 20 mg hard capsules: Each capsule contains 20 mg temozolomide.
Temozolomid Teva 20 mg tvrde kapsule: jedna kapsula sadrži 20 mg temozolomida.
Temozolomide Teva 5 mg hard capsules Each hard capsule contains 5 mg temozolomide.
Temozolomid Teva 5 mg tvrde kapsule Jedna tvrda kapsula sadrži 5 mg temozolomida.
Temozolomide Teva 140 mg hard capsules: Each capsule contains 140 mg temozolomide.
Temozolomid Teva 140 mg tvrde kapsule: jedna kapsula sadrži 140 mg temozolomida.
The hard capsules have a white opaque body and cap with two stripes in black ink on the cap and with “T 250 mg” in black ink on the body.
Tvrde kapsule imaju bijelo neprozirno tijelo i kapicu, s dvije crne linije na kapici i crnom oznakom "T 250 mg" na tijelu kapsule.
Temozolomide Teva 250 mg hard capsules have a white opaque body and cap with two stripes in black ink on the cap and with “T 250 mg” in black ink on the body.
Temozolomid Teva 250 mg tvrde kapsule imaju bijelo neprozirno tijelo i kapicu, s dvije crne linije na kapici te crnom oznakom „T 250 mg“ na tijelu kapsule.
Temozolomide Teva 250 mg hard capsules: (including printing ink): gelatin, titanium dioxide (E171), shellac, propylene glycol, black iron oxide (E172), Ammonium hydroxide (E527).
Temozolomid Teva 250 mg tvrde kapsule: (uključujući tintu za označavanje): želatina, titanijev dioksid (E171), šelak, propilenglikol, crni željezov oksid (E172).
Sodium starch glycolate Type A Colloidal anhydrous silica Tartaric acid
Sadržaj kapsule laktoza natrijev škroboglikolat, vrste A silicijev dioksid, koloidni, bezvodni tartaratna kiselina stearatna kiselina
Temozolomide Teva 180 mg hard capsules: Each capsule contains 180 mg temozolomide.
Temozolomid Teva 180 mg tvrde kapsule: jedna kapsula sadrži 180 mg temozolomida.
Excipient with known effect Each hard capsule contains 87 mg of lactose.
Jedna tvrda kapsula sadrži 87 mg laktoze.
Temozolomide Teva 250 mg hard capsules: Each capsule contains 250 mg temozolomide.
Temozolomid Teva 250 mg tvrde kapsule: jedna kapsula sadrži 250 mg temozolomida.
Temozolomide Teva 5 mg hard capsules Temozolomide
Temozolomid Teva 5 mg tvrde kapsule temozolomid
Temozolomide Teva 5 mg hard capsules have a white opaque body and cap with two stripes in green ink on the cap and with “T 5 mg” in green ink on the body.
Temozolomid Teva 5 mg tvrde kapsule imaju bijelo neprozirno tijelo i kapicu, s dvije zelene linije na kapici te zelenom oznakom „T 5 mg“ na tijelu kapsule.
Temozolomide Teva 180 mg hard capsules
Temozolomid Teva 180 mg tvrde kapsule
Cerebral haemorrhage, hypertension Embolism pulmonary, oedema, oedema peripheral
Plućna embolija, edem, periferni edem
Temozolomide Teva 100 mg hard capsules
Temozolomid Teva 100 mg tvrde kapsule
Temozolomide Teva 20 mg hard capsules Temozolomide
Temozolomid Teva 20 mg tvrde kapsule temozolomid
Temozolomide Teva 5 mg hard capsules: Each capsule contains 5 mg temozolomide.
Temozolomid Teva 5 mg tvrde kapsule: jedna kapsula sadrži 5 mg temozolomida.
In a 400 subject recurrent glioma data set, Grade 4 neutropenia occurred in 8% of female vs 4% of male subjects and Grade 4 thrombocytopenia in 8% of female vs 3% of male subjects in the first cycle of therapy.
žena naspram 4% muškaraca, a trombocitopenija stupnja 4 u 8% žena naspram 3% muškaraca.
Excipient with known effect Each hard capsule contains 84 mg of lactose.
Jedna tvrda kapsula sadrži 84 mg laktoze.
Temozolomide Teva 100 mg hard capsules: Each capsule contains 100 mg temozolomide.
Temozolomid Teva 100 mg tvrde kapsule: jedna kapsula sadrži 100 mg temozolomida.
Investigations Common:
Ostale nuspojave:
Temozolomide Teva 250 mg hard capsules Temozolomide
Temozolomid Teva 250 mg tvrde kapsule temozolomid
Temozolomide Teva 140 mg hard capsules Temozolomide
Temozolomid Teva 140 mg tvrde kapsule temozolomid
Respiratory, thoracic and mediastinal disorders Very rare:
Poremećaji dišnog sustava, prsišta i sredoprsja Često:
Adverse reactions in patients with recurrent or progressive malignant glioma Infections and infestations
Tablica 5. Nuspojave u bolesnika s recidivirajućim ili progresivnim malignim gliomom
Oral use.
Citotoksično.
Temozolomide Teva 140 mg hard capsules have a white opaque body and cap with two stripes in blue ink on the cap and with “T 140 mg” in blue ink on the body.
Temozolomid Teva 140 mg tvrde kapsule imaju bijelo neprozirno tijelo i kapicu, s dvije plave linije na kapici te plavom oznakom „T 140 mg“ na tijelu kapsule.
TMZ is to be discontinued if: dose level -1 (100 mg/m²) still results in unacceptable toxicity the same Grade 3 non-haematological toxicity (except for alopecia, nausea, vomiting) recurs after dose reduction.
• ako se nakon smanjenja doze ponovno jave isti nehematološki toksični učinci stupnja 3 (osim alopecije, mučnine i povraćanja)
Temozolomide Teva 100 mg hard capsules Temozolomide
Temozolomid Teva 100 mg tvrde kapsule temozolomid
Temozolomide Teva 180 mg hard capsules Temozolomide
Temozolomid Teva 180 mg tvrde kapsule temozolomid
- as you should be observed closely for the development of a serious form of chest infection called Pneumocystis jirovecii pneumonia (PCP).
treba pomno nadzirati zbog mogućeg razvoja Pneumocystis jirovecii pneumonije, bez obzira na režim doziranja.
There is limited information in patients over 3 years of age who have taken Temozolomide Teva.
Informacije o primjeni lijeka Temozolomid Teva u djece starije od 3 godine su ograničene.
Temozolomide Teva 180 mg hard capsules have a white opaque body and cap with two stripes in red ink on the cap and with “T 180 mg” in red ink on the body.
Temozolomid Teva 180 mg tvrde kapsule imaju bijelo neprozirno tijelo i kapicu, s dvije crvene linije na kapici te crvenom oznakom „T 180 mg“ na tijelu kapsule.
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
PRILOG II. A. PROIZVOĐAČ(I) ODGOVORAN(NI) ZA PUŠTANJE SERIJE LIJEKA U PROM ET B.
b:
NN:
Your blood will be tested frequently during treatment to monitor the side effects of Temozolomide Teva on your blood cells.
Tijekom liječenja će se često provoditi krvne pretrage radi praćenja nuspojava lijeka Temozolomid Teva na krvne stanice. - jer može postojati malen rizik od razvoja drugih promjena krvnih stanica, uključujući leukemiju.
The hard capsules have a white opaque body and cap with two stripes in green ink on the cap and with “T 5 mg” in green ink on the body.
Tvrde kapsule imaju bijelo neprozirno tijelo i kapicu, s dvije zelene linije na kapici te zelenom oznakom „T 5 mg“ na tijelu kapsule.
EU/1/09/606/011 5 capsules EU/1/09/606/012 20 capsules
EU/1/09/606/011 5 kapsula EU/1/09/606/012 20 kapsula
Haemorrhage, oedema, oedema leg Haemorrhage, deep venous thrombosis, oedema leg
Krvarenje, tromboza dubokih vena, edem nogu
Temozolomide Teva 20 mg hard capsules have a white opaque body and cap with two stripes in orange ink on the cap and with “T 20 mg” in orange ink on the body.
Temozolomid Teva 20 mg tvrde kapsule imaju bijelo neprozirno tijelo i kapicu, s dvije narančaste linije na kapici te narančastom oznakom „T 20 mg“ na tijelu kapsule.
- absolute neutrophil count (ANC) ≥ 1.5 x 109/l - thrombocyte count ≥ 100 x 109/l
(osim za alopeciju, mučninu i povraćanje) te ako je apsolutni broj neutrofila (ABN) ≥ 1,5 x 109/l, a broj trombocita ≥ 100 x 109/l.
Opportunistic infections, including PCP
Oportunističke infekcije i reaktivacija infekcija
Fever, asthenia, rigors, malaise, pain, taste perversion
Vrućica, astenija, tresavica, malaksalost, bol, promjena osjeta okusa
Temozolomide Teva 100 mg hard capsules have a white opaque body and cap with two stripes in pink ink on the cap and with “T 100 mg” in pink ink on the body.
Temozolomid Teva 100 mg tvrde kapsule imaju bijelo neprozirno tijelo i kapicu, s dvije ružičaste linije na kapici te ružičastom oznakom „T 100 mg“ na tijelu kapsule.
The hard capsules have a white opaque body and cap with two stripes in red ink on the cap and with “T 180 mg” in red ink on the body.
Tvrde kapsule imaju bijelo neprozirno tijelo i kapicu, s dvije crvene linije na kapici te crvenom oznakom "T 180 mg" na tijelu kapsule.
Very rare cases of lung side effects have been observed with Temozolomide Teva.
Pri primjeni lijeka Temozolomid Teva vrlo rijetko su primijećene nuspojave na plućima.
At the start of Cycle 2, the dose is escalated to 200 mg/m² if the CTC nonhaematological toxicity for Cycle 1 is Grade ≤ 2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/l, and the thrombocyte count is
Na početku drugog ciklusa doza se povećava na 200 mg/m2 ako je CTC stupanj nehematološke toksičnosti za prvi ciklus bio ≤ 2
Shellac
Dizurija
The hard capsules have a white opaque body and cap with two stripes in orange ink on the cap and with “T 20 mg” in orange ink on the body.
Tvrde kapsule imaju bijelo neprozirno tijelo i kapicu, s dvije narančaste linije na kapici te narančastom oznakom "T 20 mg" na tijelu kapsule.
The Temozolomide Teva dose may be adjusted, delayed or stopped depending on your blood counts and how you tolerate your medicine during each treatment cycle.
Ovisno o broju Vaših krvnih stanica i o tome kako podnosite lijek u svakom terapijskom ciklusu, može se prilagoditi doza lijeka Temozolomid Teva, odnosno odgoditi ili prekinuti uzimanje lijeka.
Convulsions, consciousness decreased, somnolence, aphasia, balance impaired, dizziness, confusion, memory impairment, concentration impaired, neuropathy, paresthesia, speech disorder, tremor
somnolencija, afazija, poremećaj ravnoteže, omaglica, konfuzija,
Each hard capsule contains 100 mg temozolomide
Jedna tvrda kapsula sadrži 100 mg temozolomida.
The hard capsules have a white body and cap with two stripes in blue ink on the cap and with “T 140 mg” in blue ink on the body.
Tvrde kapsule imaju bijelo neprozirno tijelo i kapicu, s dvije plave linije na kapici te plavom oznakom "T 140 mg" na tijelu kapsule.
Then you will have 23 days without Temozolomide Teva.
Zatim slijede 23 dana bez uzimanja lijeka Temozolomid Teva, što čini ukupno 28 dana terapijskog ciklusa.
The hard capsules have a white opaque body and cap with two stripes in pink ink on the cap and with “T 100 mg” in pink ink on the body.
Tvrde kapsule imaju bijelo neprozirno tijelo i kapicu, s dvije ružičaste linije na kapici te ružičastom oznakom " T 100 mg" na tijelu kapsule.
Excipient with known effect Each hard capsule contains 150 mg of lactose.
Jedna tvrda kapsula sadrži 150 mg laktoze.
Black iron oxide (E172) Propylene Glycol Ammonium hydroxide (E527)
Tinta za označavanje šelak željezov oksid, crni (E172) propilenglikol aluminijev hidroksid
Temozolomide Teva 140 mg hard capsules: (including printing ink): gelatin, titanium dioxide (E171), shellac, propylene glycol, Indigo carmine (E132) aluminium lake Temozolomide Teva 180 mg hard capsules: (including printing ink): gelatin, titanium dioxide (E171), shellac, propylene glycol, red iron oxide (E172)
Temozolomid Teva 140 mg tvrde kapsule: (uključujući tintu za označavanje): želatina, titanijev dioksid (E171), šelak, propilenglikol, indigo carmine (E132) aluminium lake.
EU/1/09/606/007 5 capsules EU/1/09/606/008 20 capsules
EU/1/09/606/007 5 kapsula EU/1/09/606/008 20 kapsula
C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
UVJETI ILI OGRANIČENJA VEZANI UZ OPSKRBU I PRIMJENU C. OSTALI UVJETI I ZAHTJEVI ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET
EU/1/09/606/003 5 capsules EU/1/09/606/004 20 capsules
EU/1/09/606/003 5 kapsula EU/1/09/606/004 20 kapsula
EU/1/09/606/009 5 capsules EU/1/09/606/010 20 capsules
EU/1/09/606/009 5 kapsula EU/1/09/606/010 20 kapsula
If you have been previously treated with chemotherapy, your first dose of Temozolomide Teva will be 150 mg/m² once daily for the first 5 days.
Temozolomid Teva bit će 150 mg/m2 jedanput na dan tijekom prvih 5 dana.
Vision blurred
Zamagljen vid
The following additional serious adverse reactions have been identified during post-marketing exposure:
Nakon stavljanja lijeka u promet zabilježene su sljedeće dodatne ozbiljne nuspojave: Tablica 6. Sažetak štetnih događaja prijavljenih nakon stavljanja temozolomida u promet*
During the concomitant phase, your doctor will start Temozolomide Teva at a dose of 75 mg/m² (usual dose).
U prvom ciklusu monoterapije TMZ se daje u dozi od 150 mg/m2
TMZ interruptiona
TMZ-a.
EU/1/09/606/005 5 capsules EU/1/09/606/006 20 capsules
EU/1/09/606/005 5 kapsula EU/1/09/606/006 20 kapsula
EU/1/09/606/001 5 capsules EU/1/09/606/002 20 capsules
EU/1/09/606/001 5 kapsula EU/1/09/606/002 20 kapsula
Very rare (<1/10,000).
naspram 10%).
Status epilepticus, extrapyramidal disorder, hemiparesis, ataxia, cognition impaired, dysphasia, gait abnormal, hyperesthesia, hypoesthesia, neurological disorder (NOS), peripheral neuropathy
hipoestezija, nespecificirani neurološki poremećaj, periferna neuropatija
10 U Powder and solvent for solution for injection
10 U Prašak i otapalo za otopinu za injekciju
2 prefilled syringes 2 reconstitution devices and 2 needles 19 G l
2 napunjene štrcaljke 2 pomagala za rekonstituciju i 2 igle 19 G1
Powder: vial (glass) Solvent: prefilled syringe (glass)
Otapalo: napunjena štrcaljka (staklo)
EU Number Invented name Strength Pharmaceutical form Route of administration Packaging
Doza Farmaceutski oblik
Gran Via Carlos III, 94 08028 Barcelona Spain
Gran Via Carlos III, 94 08028 Barcelona
Farmakeytika Proionta Epe,
S.M. Farmakeytika Proionta Epe,
Estrada Consiglieri Pedroso, 80 - Lt. 3 - Armz.
Estrada Consiglieri Pedroso, 80 - Lt.
Avenida Mestre Cid, 8 - 1º Esq. Frente
Avenida Mestre Cid, 8 - 1º Esq.
Slovenia KRKA, d.d., Novo mesto Šmarješka cesta 6
Češka Republika Krka, d.d., Novo mesto Šmarješka cesta 6
Austria ratiopharm Arzneimittel Vertriebs-GmbH Albert Schweitzergasse 3 Vienna
Austrija ratiopharm Arzneimittel Vertriebs-GmbH Albert Schweitzergasse 3 Vienna
Dolni Mėcholupy 102 37 Praha 10
Dolni Mėcholupy 102 37 Prague 10
Hungary Pharma-Regist Kft., Október 6. u. 7.
Pharma-Regist Kft., Október 6. u. 7. Budapest
Irakliou 425 & Olympias 28, 14122 N. Iraklio, Greece
Irakliou 425 & Olympias 28, 14122 N.
4 mg + 3,86 mg solution for injection injection use
4 mg + 3,86 mg otopina za injekciju za injekciju
Sopharma Warszawa Sp. z o.o.
Sopharma Warszawa Sp. z o.o. ul.
V. Emanuele Ii, 72 10121 Torino
Emanuele Ii, 72 10121 Torino
Estrada de Paço de Arcos, 88 - Cacém Park, Armazém 27 2735-307 Agualva-Cacém Portugal
Estrada de Paço de Arcos, 88 - Cacém Park, Armazém 27 2735-307 Agualva-Cacém Portugal bromheksin
8 mg + 500 mg capsule, hard
8 mg + 500 mg kapsula, tvrda
São Martinho do Bispo 3045-016 Coimbra Portugal
São Martinho do Bispo 3045-016 Coimbra Portugal bromheksin
4 mg per tablet
4 mg po tableti
Prilaz baruna Filipovića 25, Zagreb
Pliva Hrvatska d.o.o. Prilaz baruna Filipovića 25, Zagreb
Egis Pharmaceuticals PLC Keresztúri út.
Češka Republika Egis Pharmaceuticals PLC Keresztúri út.
Poligono Indistrial Areta 31620 Huarte Pamplona Navarrra
Poligono Indistrial Areta 31620 Huarte Pamplona
Angelini Pharma Hellas Anonimi Biomhxaniki Etaireia Paragogis & Emporias Farmakon, Achaias & Trizinias, 14564, N. Kiffisia, Greece
Angelini Pharma Hellas Anonimi Biomhxaniki Etaireia Paragogis & Emporias Farmakon, Achaias & Trizinias, 14564, N.
G. L. Pharma GmbH, Schlossplatz 1, 8502 Lannach,
L. Pharma GmbH, Schlossplatz 1, 8502 Lannach,
Cuatro amigos 7, escalera 2, 1ºD
DESMA LABORATORIO FARMACEUTICO, S.L. Cuatro amigos 7, escalera 2, 1ºD
8 mg/ml 1,5 mg/ml 0,75 mg/ml mg/ml mg/ml mg/ml mg/ml oral drops
8 mg/ml 1,5 mg/ml 0,75 mg/ml mg/ml mg/ml mg/ml mg/ml oralne kapi
7,5mg/5ml, 0,0001g oral liquid
7,5mg/5ml, 0,0001g oralna tekućina
Rua Aquilino Ribeiro, 6-A 2790-027 Carnaxide Portugal
Rua Aquilino Ribeiro, 6-A 2790-027 Carnaxide Portugal ambroksol
Romania SOLACIUM PHARMA S.R.L., str. Calea Rahovei nr. 266268, corp. 60, axele A-B, stalpii 11-16, etaj II, birou 1, sector 5, Bucuresti
SOLACIUM PHARMA S.R.L., str. Calea Rahovei nr. 266268, corp. 60, axele A-B, stalpii 11-16, etaj II, birou 1, sector 5, Bucuresti Romania bromheksinklorid BROMHEXIN SOLACIUM 8 mg
Laboratórios Basi - Indústria Farmacêutica, S.A Parque Industrial Manuel Lourenço Ferreira, Lote 15 3450-232 Mortágua Portugal
Laboratórios Basi - Indústria Farmacêutica, S.A Parque Industrial Manuel Lourenço Ferreira, Lote 15 3450-232 Mortágua Portugal bromheksin
Germany esparma GmbH Seepark 7
Njemačka esparma GmbH Seepark 7
Hlohovec 920 27 Slovak Republic bromhexine hydrochloride, mentholum, oleum foeniculi, oleum anisi, oleum origani, oleum menthae piperitae, oleum eucalypti
Hlohovec 920 27 Slovak Republic bromheksinklorid, mentol (mentholum), ulje komorača (oleum foeniculi), ulje anisa (oleum anisi), ulje origana (oleum origani), ulje paprene metvice (oleum Menthae piperitae), ulje eukaliptusa (oleum eucalypti)
LABORATORIOS CINFA S.A. Olaz -Chipi, 10
Olaz -Chipi, 10
Rua Sebastião e Silva, 25 2745-838 Massamá Portugal
Rua Sebastião e Silva, 25 2745-838 Massamá Portugal ambroksol
1/12Queluz de Baixo 2745-553 Barcarena Portugal
3 - Armz. 1/12Queluz de Baixo 2745-553 Barcarena Portugal ambroksol
Laboratórios AzevedosIndústria Farmacêutica, S.A. Edifícios Azevedos - Estrada Nacional 117-2, Alfragide 2614-503 Amadora Portugal
Laboratórios AzevedosIndústria Farmacêutica, S.A. Edifícios Azevedos - Estrada Nacional 117-2, Alfragide 2614-503 Amadora Portugal ambroksol
& Eir.
Ioul. & Eir.
LABORATORIOS CINFA S.A. Olaz -Chipi, 10 Poligono Indistrial Areta 31620 Huarte-Pamplona Navarra
Olaz -Chipi, 10 Poligono Indistrial Areta 31620 Huarte-Pamplona Navarra
Help Αβεε, Valaoritou 10, 14452, Metamorfosi, Greece
Help Αβεε, Valaoritou 10, 14452, Metamorfosi, Greece bromheksin
12, Korinthou Str., New Psychico, Athens 15451, Greece
12, Korinthou Str., New Psychico, Athens 15451, Greece ambroksolklorid Kriolen
Agiou Orous 43-45, 18545 Peireas, Atiiki, Greece
Agiou Orous 43-45, 18545 Peireas, Atiiki, Greece ambroksolklorid Mucovix
3450-336 Sobral - Mortágua Portugal
3450-336 Sobral - Mortágua Portugal ambroksol
Box 51706, 3508 Limassol, Cyprus
Box 51706, 3508 Limassol, Cyprus bromheksinklorid BP
Medochemie Ltd 1-10 Constantinoupoleos Street P.O.BOX 51409 3505 Lemesos Cyprus
Medochemie Ltd 1-10 Constantinoupoleos Street P.O.BOX 51409 3505 Lemesos Cyprus ambroksolklorid Medovent
Tatoiou Street, 18th Km National Road Athens-Lamia, 14571 Nea Erythrea, Greece
Tatoiou Street, 18th Km National Road Athens-Lamia, 14571 Nea Erythrea, Greece ambroksolklorid Broncolyn
37 Pireos Str, 183 46, Moschato, Athens, Greece
37 Pireos Str, 183 46, Moschato, Athens, Greece bromheksinklorid Bronchotussine
Hungary PannonPharma Kft. Pannonpharma út 1.
Pannonpharma út 1.
Rua Henrique Paiva Couceiro, 27 - Venda Nova 2700-451 Amadora Portugal
Rua Henrique Paiva Couceiro, 27 - Venda Nova 2700-451 Amadora Portugal ambroksol
AS Grindeks Krustpils 53 1057 Riga Latvia
AS Grindeks Krustpils 53 1057 Riga Latvia bromheksin
Coup Abee, Ag. Barbaras 53-55, 17235 Dafni, Greece
Coup Abee, Ag. Barbaras 53-55, 17235 Dafni, Greece ambroksolklorid Nibren